Utilizing lipid-crystal nano-particle cochleates, our LNC platform works to encapsulate existing drugs and resolve significant drug delivery challenges. This technology can help make therapeutics safer, less toxic, more tolerable, and orally bioavailable.
We are advancing the following drug candidates born from our proprietary LNC platform.
An oral encochleated formulation of amphotericin B for treating serious invasive fungal infections (IFIs). Phase 3 registration trial of MAT2203 for treatment of cryptococcal meningitis to commence Q1 2023Learn More
An oral encochleated formulation of amikacin for the treatment of Non-Tuberculous Mycobacterium (NTM).Learn More